XIAN, Jiangxi, China, Dec. 21, 2022 (GLOBE NEWSWIRE) — UNIVERSE PHARMACEUTICALS INC (the “Company”) (Nasdaq: UPC ), a pharmaceutical producer and distributor in China, today announced that six of the Company’s products are available for patients with COVID-19. was included in the first edition of the Drug Catalog (“Catalog”), published by the Beijing Health Commission on December 12, 2022. Products included are Banlangen Granules, Strong Loquat Extract, Pediatric Paracetamol, Vitamin C Inkiao Tablets, Acetaminophen Tablets and Metamizole Sodium Tablets.
The catalog supplements the list of drugs recommended in the Ninth Edition of the National Diagnosis and Treatment Plan. The catalog recommends 67 types of Chinese medicine products for six different types of medical symptoms, such as fever and sore throat, and 41 types of Western medicine products for four types of clinical symptoms, such as cough and phlegm. Apart from hospitals, patients can also buy cataloged medicines from channels like retail pharmacies and e-commerce platforms as per their own needs.
Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC commented, “We are delighted to include our products in the catalog. Currently, orders for our three products, Banlangen Granules, Strong Loquat Extract and Pediatric Paracetamol are steadily increasing. We will optimize the supply chain system to meet the growing demand and strive to ensure adequate supply of these three products to combat the symptoms of Covid-19.”
About UNIVERSE PHARMACEUTICALS INC
UNIVERSE PHARMACEUTICALS INC., headquartered in Xi’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivative products aimed at the elderly to address their physical conditions in the aging process and promote their general well-being. The Company distributes and sells biomedical drugs, medical devices, traditional Chinese medicine pills and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the company’s products are sold in 30 provinces in China. For more information, visit the company’s website http://www.universe-pharmacy.com/.
future plans
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and assumptions about future events and financial trends that the Company believes could affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may be“ “willpower,“ “hope,“ “forecast,“ “target,“ “estimate,“ “intention“ “the plan“ “faith,“ “possible,“ “continue,“ “is/is likely to be“ or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will be accurate, and the Company cautions investors that actual results may differ materially from anticipated results and encourages investors to review other factors that may affect the Company’s performance. may affect its future results in the registration statement and its other filings US Securities and Exchange Commission.
For more information contact:
Ascent Investors Relations LLC
Tina Xiao
the president
Phone: 917-609-0333
Email: [email protected]
